Research ArticleArticle
Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase 3 Studies
Georg Schett, Xenofon Baraliakos, Filip Van den Bosch, Atul Deodhar, Mikkel Østergaard, Ayan Das Gupta, Shephard Mpofu, Todd Fox, Adam Winseck, Brian Porter, Abhijit Shete and Lianne S. Gensler
The Journal of Rheumatology March 2021, jrheum.201111; DOI: https://doi.org/10.3899/jrheum.201111
Georg Schett
This study was funded by Novartis Pharma AG, Basel, Switzerland. G. Schett, MD, Department of Internal Medicine, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany; F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, and VIB Center for Inflammation Research, Ghent, Belgium; A. Deodhar, MD, Oregon Health & Science University, Portland, Oregon, USA; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark; A. Das Gupta, PhD, Novartis Healthcare Pvt. Ltd., Hyderabad, India; S. Mpofu, MD, T. Fox, RPh, PharmB, ACPR, A. Shete, MD, Novartis Pharma AG, Basel, Switzerland; A. Winseck, PhD, B. Porter, MD, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; L.S. Gensler, MD, University of California, San Francisco, University of California, California, USA. GS has received grant/research support from BMS, Celgene, GSK, Eli Lilly, and Novartis; consultancy fees for AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB; and speakers bureau fees from AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and Pfizer. XB has been a consultant for AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, UCB, and received speakers bureau fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB. FVDB has received consultant/speaker fees from AbbVie, BMS, Celgene, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sanofi, and UCB. AD has received grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and has been a consultant for AbbVie, Amgen, Boheringer Ingelheim, Celgene, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, and UCB. LG has received grant/research support from Novartis, Pfizer, and UCB, and has been a consultant for AbbVie, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB. MØ has received speaker/consultant fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB; and research grants from AbbVie, Celgene, Centocor, Merck, and Novartis. ADG is an employee of Novartis. SM, TF, AW, BP, and AS are employees and shareholders of Novartis. Address correspondence to Dr. G. Schett, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich Alexander University, Krankenhausstr. 12, D-91054 Erlangen, Germany. Email: Georg.Schett@uk-erlangen.de. Accepted for publication February 26, 2021.
Xenofon Baraliakos
This study was funded by Novartis Pharma AG, Basel, Switzerland. G. Schett, MD, Department of Internal Medicine, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany; F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, and VIB Center for Inflammation Research, Ghent, Belgium; A. Deodhar, MD, Oregon Health & Science University, Portland, Oregon, USA; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark; A. Das Gupta, PhD, Novartis Healthcare Pvt. Ltd., Hyderabad, India; S. Mpofu, MD, T. Fox, RPh, PharmB, ACPR, A. Shete, MD, Novartis Pharma AG, Basel, Switzerland; A. Winseck, PhD, B. Porter, MD, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; L.S. Gensler, MD, University of California, San Francisco, University of California, California, USA. GS has received grant/research support from BMS, Celgene, GSK, Eli Lilly, and Novartis; consultancy fees for AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB; and speakers bureau fees from AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and Pfizer. XB has been a consultant for AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, UCB, and received speakers bureau fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB. FVDB has received consultant/speaker fees from AbbVie, BMS, Celgene, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sanofi, and UCB. AD has received grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and has been a consultant for AbbVie, Amgen, Boheringer Ingelheim, Celgene, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, and UCB. LG has received grant/research support from Novartis, Pfizer, and UCB, and has been a consultant for AbbVie, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB. MØ has received speaker/consultant fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB; and research grants from AbbVie, Celgene, Centocor, Merck, and Novartis. ADG is an employee of Novartis. SM, TF, AW, BP, and AS are employees and shareholders of Novartis. Address correspondence to Dr. G. Schett, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich Alexander University, Krankenhausstr. 12, D-91054 Erlangen, Germany. Email: Georg.Schett@uk-erlangen.de. Accepted for publication February 26, 2021.
Filip Van den Bosch
This study was funded by Novartis Pharma AG, Basel, Switzerland. G. Schett, MD, Department of Internal Medicine, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany; F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, and VIB Center for Inflammation Research, Ghent, Belgium; A. Deodhar, MD, Oregon Health & Science University, Portland, Oregon, USA; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark; A. Das Gupta, PhD, Novartis Healthcare Pvt. Ltd., Hyderabad, India; S. Mpofu, MD, T. Fox, RPh, PharmB, ACPR, A. Shete, MD, Novartis Pharma AG, Basel, Switzerland; A. Winseck, PhD, B. Porter, MD, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; L.S. Gensler, MD, University of California, San Francisco, University of California, California, USA. GS has received grant/research support from BMS, Celgene, GSK, Eli Lilly, and Novartis; consultancy fees for AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB; and speakers bureau fees from AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and Pfizer. XB has been a consultant for AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, UCB, and received speakers bureau fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB. FVDB has received consultant/speaker fees from AbbVie, BMS, Celgene, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sanofi, and UCB. AD has received grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and has been a consultant for AbbVie, Amgen, Boheringer Ingelheim, Celgene, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, and UCB. LG has received grant/research support from Novartis, Pfizer, and UCB, and has been a consultant for AbbVie, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB. MØ has received speaker/consultant fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB; and research grants from AbbVie, Celgene, Centocor, Merck, and Novartis. ADG is an employee of Novartis. SM, TF, AW, BP, and AS are employees and shareholders of Novartis. Address correspondence to Dr. G. Schett, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich Alexander University, Krankenhausstr. 12, D-91054 Erlangen, Germany. Email: Georg.Schett@uk-erlangen.de. Accepted for publication February 26, 2021.
Atul Deodhar
This study was funded by Novartis Pharma AG, Basel, Switzerland. G. Schett, MD, Department of Internal Medicine, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany; F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, and VIB Center for Inflammation Research, Ghent, Belgium; A. Deodhar, MD, Oregon Health & Science University, Portland, Oregon, USA; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark; A. Das Gupta, PhD, Novartis Healthcare Pvt. Ltd., Hyderabad, India; S. Mpofu, MD, T. Fox, RPh, PharmB, ACPR, A. Shete, MD, Novartis Pharma AG, Basel, Switzerland; A. Winseck, PhD, B. Porter, MD, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; L.S. Gensler, MD, University of California, San Francisco, University of California, California, USA. GS has received grant/research support from BMS, Celgene, GSK, Eli Lilly, and Novartis; consultancy fees for AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB; and speakers bureau fees from AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and Pfizer. XB has been a consultant for AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, UCB, and received speakers bureau fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB. FVDB has received consultant/speaker fees from AbbVie, BMS, Celgene, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sanofi, and UCB. AD has received grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and has been a consultant for AbbVie, Amgen, Boheringer Ingelheim, Celgene, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, and UCB. LG has received grant/research support from Novartis, Pfizer, and UCB, and has been a consultant for AbbVie, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB. MØ has received speaker/consultant fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB; and research grants from AbbVie, Celgene, Centocor, Merck, and Novartis. ADG is an employee of Novartis. SM, TF, AW, BP, and AS are employees and shareholders of Novartis. Address correspondence to Dr. G. Schett, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich Alexander University, Krankenhausstr. 12, D-91054 Erlangen, Germany. Email: Georg.Schett@uk-erlangen.de. Accepted for publication February 26, 2021.
Mikkel Østergaard
This study was funded by Novartis Pharma AG, Basel, Switzerland. G. Schett, MD, Department of Internal Medicine, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany; F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, and VIB Center for Inflammation Research, Ghent, Belgium; A. Deodhar, MD, Oregon Health & Science University, Portland, Oregon, USA; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark; A. Das Gupta, PhD, Novartis Healthcare Pvt. Ltd., Hyderabad, India; S. Mpofu, MD, T. Fox, RPh, PharmB, ACPR, A. Shete, MD, Novartis Pharma AG, Basel, Switzerland; A. Winseck, PhD, B. Porter, MD, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; L.S. Gensler, MD, University of California, San Francisco, University of California, California, USA. GS has received grant/research support from BMS, Celgene, GSK, Eli Lilly, and Novartis; consultancy fees for AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB; and speakers bureau fees from AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and Pfizer. XB has been a consultant for AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, UCB, and received speakers bureau fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB. FVDB has received consultant/speaker fees from AbbVie, BMS, Celgene, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sanofi, and UCB. AD has received grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and has been a consultant for AbbVie, Amgen, Boheringer Ingelheim, Celgene, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, and UCB. LG has received grant/research support from Novartis, Pfizer, and UCB, and has been a consultant for AbbVie, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB. MØ has received speaker/consultant fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB; and research grants from AbbVie, Celgene, Centocor, Merck, and Novartis. ADG is an employee of Novartis. SM, TF, AW, BP, and AS are employees and shareholders of Novartis. Address correspondence to Dr. G. Schett, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich Alexander University, Krankenhausstr. 12, D-91054 Erlangen, Germany. Email: Georg.Schett@uk-erlangen.de. Accepted for publication February 26, 2021.
Ayan Das Gupta
This study was funded by Novartis Pharma AG, Basel, Switzerland. G. Schett, MD, Department of Internal Medicine, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany; F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, and VIB Center for Inflammation Research, Ghent, Belgium; A. Deodhar, MD, Oregon Health & Science University, Portland, Oregon, USA; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark; A. Das Gupta, PhD, Novartis Healthcare Pvt. Ltd., Hyderabad, India; S. Mpofu, MD, T. Fox, RPh, PharmB, ACPR, A. Shete, MD, Novartis Pharma AG, Basel, Switzerland; A. Winseck, PhD, B. Porter, MD, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; L.S. Gensler, MD, University of California, San Francisco, University of California, California, USA. GS has received grant/research support from BMS, Celgene, GSK, Eli Lilly, and Novartis; consultancy fees for AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB; and speakers bureau fees from AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and Pfizer. XB has been a consultant for AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, UCB, and received speakers bureau fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB. FVDB has received consultant/speaker fees from AbbVie, BMS, Celgene, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sanofi, and UCB. AD has received grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and has been a consultant for AbbVie, Amgen, Boheringer Ingelheim, Celgene, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, and UCB. LG has received grant/research support from Novartis, Pfizer, and UCB, and has been a consultant for AbbVie, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB. MØ has received speaker/consultant fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB; and research grants from AbbVie, Celgene, Centocor, Merck, and Novartis. ADG is an employee of Novartis. SM, TF, AW, BP, and AS are employees and shareholders of Novartis. Address correspondence to Dr. G. Schett, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich Alexander University, Krankenhausstr. 12, D-91054 Erlangen, Germany. Email: Georg.Schett@uk-erlangen.de. Accepted for publication February 26, 2021.
Shephard Mpofu
This study was funded by Novartis Pharma AG, Basel, Switzerland. G. Schett, MD, Department of Internal Medicine, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany; F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, and VIB Center for Inflammation Research, Ghent, Belgium; A. Deodhar, MD, Oregon Health & Science University, Portland, Oregon, USA; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark; A. Das Gupta, PhD, Novartis Healthcare Pvt. Ltd., Hyderabad, India; S. Mpofu, MD, T. Fox, RPh, PharmB, ACPR, A. Shete, MD, Novartis Pharma AG, Basel, Switzerland; A. Winseck, PhD, B. Porter, MD, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; L.S. Gensler, MD, University of California, San Francisco, University of California, California, USA. GS has received grant/research support from BMS, Celgene, GSK, Eli Lilly, and Novartis; consultancy fees for AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB; and speakers bureau fees from AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and Pfizer. XB has been a consultant for AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, UCB, and received speakers bureau fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB. FVDB has received consultant/speaker fees from AbbVie, BMS, Celgene, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sanofi, and UCB. AD has received grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and has been a consultant for AbbVie, Amgen, Boheringer Ingelheim, Celgene, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, and UCB. LG has received grant/research support from Novartis, Pfizer, and UCB, and has been a consultant for AbbVie, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB. MØ has received speaker/consultant fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB; and research grants from AbbVie, Celgene, Centocor, Merck, and Novartis. ADG is an employee of Novartis. SM, TF, AW, BP, and AS are employees and shareholders of Novartis. Address correspondence to Dr. G. Schett, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich Alexander University, Krankenhausstr. 12, D-91054 Erlangen, Germany. Email: Georg.Schett@uk-erlangen.de. Accepted for publication February 26, 2021.
Todd Fox
This study was funded by Novartis Pharma AG, Basel, Switzerland. G. Schett, MD, Department of Internal Medicine, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany; F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, and VIB Center for Inflammation Research, Ghent, Belgium; A. Deodhar, MD, Oregon Health & Science University, Portland, Oregon, USA; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark; A. Das Gupta, PhD, Novartis Healthcare Pvt. Ltd., Hyderabad, India; S. Mpofu, MD, T. Fox, RPh, PharmB, ACPR, A. Shete, MD, Novartis Pharma AG, Basel, Switzerland; A. Winseck, PhD, B. Porter, MD, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; L.S. Gensler, MD, University of California, San Francisco, University of California, California, USA. GS has received grant/research support from BMS, Celgene, GSK, Eli Lilly, and Novartis; consultancy fees for AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB; and speakers bureau fees from AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and Pfizer. XB has been a consultant for AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, UCB, and received speakers bureau fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB. FVDB has received consultant/speaker fees from AbbVie, BMS, Celgene, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sanofi, and UCB. AD has received grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and has been a consultant for AbbVie, Amgen, Boheringer Ingelheim, Celgene, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, and UCB. LG has received grant/research support from Novartis, Pfizer, and UCB, and has been a consultant for AbbVie, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB. MØ has received speaker/consultant fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB; and research grants from AbbVie, Celgene, Centocor, Merck, and Novartis. ADG is an employee of Novartis. SM, TF, AW, BP, and AS are employees and shareholders of Novartis. Address correspondence to Dr. G. Schett, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich Alexander University, Krankenhausstr. 12, D-91054 Erlangen, Germany. Email: Georg.Schett@uk-erlangen.de. Accepted for publication February 26, 2021.
Adam Winseck
This study was funded by Novartis Pharma AG, Basel, Switzerland. G. Schett, MD, Department of Internal Medicine, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany; F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, and VIB Center for Inflammation Research, Ghent, Belgium; A. Deodhar, MD, Oregon Health & Science University, Portland, Oregon, USA; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark; A. Das Gupta, PhD, Novartis Healthcare Pvt. Ltd., Hyderabad, India; S. Mpofu, MD, T. Fox, RPh, PharmB, ACPR, A. Shete, MD, Novartis Pharma AG, Basel, Switzerland; A. Winseck, PhD, B. Porter, MD, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; L.S. Gensler, MD, University of California, San Francisco, University of California, California, USA. GS has received grant/research support from BMS, Celgene, GSK, Eli Lilly, and Novartis; consultancy fees for AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB; and speakers bureau fees from AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and Pfizer. XB has been a consultant for AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, UCB, and received speakers bureau fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB. FVDB has received consultant/speaker fees from AbbVie, BMS, Celgene, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sanofi, and UCB. AD has received grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and has been a consultant for AbbVie, Amgen, Boheringer Ingelheim, Celgene, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, and UCB. LG has received grant/research support from Novartis, Pfizer, and UCB, and has been a consultant for AbbVie, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB. MØ has received speaker/consultant fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB; and research grants from AbbVie, Celgene, Centocor, Merck, and Novartis. ADG is an employee of Novartis. SM, TF, AW, BP, and AS are employees and shareholders of Novartis. Address correspondence to Dr. G. Schett, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich Alexander University, Krankenhausstr. 12, D-91054 Erlangen, Germany. Email: Georg.Schett@uk-erlangen.de. Accepted for publication February 26, 2021.
Brian Porter
This study was funded by Novartis Pharma AG, Basel, Switzerland. G. Schett, MD, Department of Internal Medicine, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany; F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, and VIB Center for Inflammation Research, Ghent, Belgium; A. Deodhar, MD, Oregon Health & Science University, Portland, Oregon, USA; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark; A. Das Gupta, PhD, Novartis Healthcare Pvt. Ltd., Hyderabad, India; S. Mpofu, MD, T. Fox, RPh, PharmB, ACPR, A. Shete, MD, Novartis Pharma AG, Basel, Switzerland; A. Winseck, PhD, B. Porter, MD, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; L.S. Gensler, MD, University of California, San Francisco, University of California, California, USA. GS has received grant/research support from BMS, Celgene, GSK, Eli Lilly, and Novartis; consultancy fees for AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB; and speakers bureau fees from AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and Pfizer. XB has been a consultant for AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, UCB, and received speakers bureau fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB. FVDB has received consultant/speaker fees from AbbVie, BMS, Celgene, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sanofi, and UCB. AD has received grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and has been a consultant for AbbVie, Amgen, Boheringer Ingelheim, Celgene, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, and UCB. LG has received grant/research support from Novartis, Pfizer, and UCB, and has been a consultant for AbbVie, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB. MØ has received speaker/consultant fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB; and research grants from AbbVie, Celgene, Centocor, Merck, and Novartis. ADG is an employee of Novartis. SM, TF, AW, BP, and AS are employees and shareholders of Novartis. Address correspondence to Dr. G. Schett, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich Alexander University, Krankenhausstr. 12, D-91054 Erlangen, Germany. Email: Georg.Schett@uk-erlangen.de. Accepted for publication February 26, 2021.
Abhijit Shete
This study was funded by Novartis Pharma AG, Basel, Switzerland. G. Schett, MD, Department of Internal Medicine, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany; F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, and VIB Center for Inflammation Research, Ghent, Belgium; A. Deodhar, MD, Oregon Health & Science University, Portland, Oregon, USA; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark; A. Das Gupta, PhD, Novartis Healthcare Pvt. Ltd., Hyderabad, India; S. Mpofu, MD, T. Fox, RPh, PharmB, ACPR, A. Shete, MD, Novartis Pharma AG, Basel, Switzerland; A. Winseck, PhD, B. Porter, MD, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; L.S. Gensler, MD, University of California, San Francisco, University of California, California, USA. GS has received grant/research support from BMS, Celgene, GSK, Eli Lilly, and Novartis; consultancy fees for AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB; and speakers bureau fees from AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and Pfizer. XB has been a consultant for AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, UCB, and received speakers bureau fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB. FVDB has received consultant/speaker fees from AbbVie, BMS, Celgene, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sanofi, and UCB. AD has received grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and has been a consultant for AbbVie, Amgen, Boheringer Ingelheim, Celgene, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, and UCB. LG has received grant/research support from Novartis, Pfizer, and UCB, and has been a consultant for AbbVie, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB. MØ has received speaker/consultant fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB; and research grants from AbbVie, Celgene, Centocor, Merck, and Novartis. ADG is an employee of Novartis. SM, TF, AW, BP, and AS are employees and shareholders of Novartis. Address correspondence to Dr. G. Schett, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich Alexander University, Krankenhausstr. 12, D-91054 Erlangen, Germany. Email: Georg.Schett@uk-erlangen.de. Accepted for publication February 26, 2021.
Lianne S. Gensler
This study was funded by Novartis Pharma AG, Basel, Switzerland. G. Schett, MD, Department of Internal Medicine, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany; F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, and VIB Center for Inflammation Research, Ghent, Belgium; A. Deodhar, MD, Oregon Health & Science University, Portland, Oregon, USA; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark; A. Das Gupta, PhD, Novartis Healthcare Pvt. Ltd., Hyderabad, India; S. Mpofu, MD, T. Fox, RPh, PharmB, ACPR, A. Shete, MD, Novartis Pharma AG, Basel, Switzerland; A. Winseck, PhD, B. Porter, MD, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; L.S. Gensler, MD, University of California, San Francisco, University of California, California, USA. GS has received grant/research support from BMS, Celgene, GSK, Eli Lilly, and Novartis; consultancy fees for AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB; and speakers bureau fees from AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, and Pfizer. XB has been a consultant for AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, UCB, and received speakers bureau fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB. FVDB has received consultant/speaker fees from AbbVie, BMS, Celgene, Galapagos, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sanofi, and UCB. AD has received grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and has been a consultant for AbbVie, Amgen, Boheringer Ingelheim, Celgene, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, and UCB. LG has received grant/research support from Novartis, Pfizer, and UCB, and has been a consultant for AbbVie, Gilead, GSK, Eli Lilly, Novartis, Pfizer, and UCB. MØ has received speaker/consultant fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB; and research grants from AbbVie, Celgene, Centocor, Merck, and Novartis. ADG is an employee of Novartis. SM, TF, AW, BP, and AS are employees and shareholders of Novartis. Address correspondence to Dr. G. Schett, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich Alexander University, Krankenhausstr. 12, D-91054 Erlangen, Germany. Email: Georg.Schett@uk-erlangen.de. Accepted for publication February 26, 2021.
Article Figures & Data
Additional Files
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase 3 Studies
Georg Schett, Xenofon Baraliakos, Filip Van den Bosch, Atul Deodhar, Mikkel Østergaard, Ayan Das Gupta, Shephard Mpofu, Todd Fox, Adam Winseck, Brian Porter, Abhijit Shete, Lianne S. Gensler
The Journal of Rheumatology Mar 2021, jrheum.201111; DOI: 10.3899/jrheum.201111
Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase 3 Studies
Georg Schett, Xenofon Baraliakos, Filip Van den Bosch, Atul Deodhar, Mikkel Østergaard, Ayan Das Gupta, Shephard Mpofu, Todd Fox, Adam Winseck, Brian Porter, Abhijit Shete, Lianne S. Gensler
The Journal of Rheumatology Mar 2021, jrheum.201111; DOI: 10.3899/jrheum.201111